Using soluble B7-H3 levels to evaluate osteosarcoma prognosis
An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma
This study is testing if measuring a protein called soluble B7-H3 in the blood can help predict how well patients with high-grade osteosarcoma will do after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05942456 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the levels of soluble B7-H3 (sB7-H3) in serum as a potential biomarker for osteosarcoma. It focuses on patients with high-grade osteosarcoma who have not received systemic treatment prior to blood sampling. The study will utilize enzyme-linked immunosorbent assay (ELISA) to measure sB7-H3 levels and assess their correlation with clinical outcomes. The goal is to better understand the clinical significance of sB7-H3 in the context of osteosarcoma treatment and prognosis.
Who should consider this trial
Good fit: Ideal candidates are patients with high-grade osteosarcoma who are treatment-naive and can tolerate standard chemotherapy protocols.
Not a fit: Patients who cannot tolerate blood drawing or have incomplete medical records may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for predicting treatment outcomes in osteosarcoma patients.
How similar studies have performed: While there is increasing evidence linking sB7-H3 to prognosis in various malignancies, the specific application to osteosarcoma is novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * High Grade osteosarcoma verified with pathologic diagnosis. * systemic treatment-naive before the first time Blood drawing. * ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy. * All radiographs are complete for clinical evaluation. Exclusion Criteria: * Patients who Can't tolerate blood drawing. * Patients without complete medical records in PKUPH system. * Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy. * other conditions that investigators think are not suitable for this study.
Where this trial is running
Beijing, Beijing Municipality
- Peking University People's Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Lu Xie, M.D.
- Email: xie.lu@hotmail.com
- Phone: +86-13401044719
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.